

AWARD NUMBER: W81XWH-16-1-0103

TITLE: Phase 2 Study of AZD2014, a Dual mTORC1/mTORC1 Inhibitor, for NF2 Patients with Progressive or Symptomatic Meningiomas

PRINCIPAL INVESTIGATOR: Scott Plotkin, MD, PhD

CONTRACTING ORGANIZATION: Massachusetts General Hospital

REPORT DATE: June 2019

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE		Form Approved OMB No. 0704-0188
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.		
1. REPORT DATE June 2019	2. REPORT TYPE Annual Report	3. DATES COVERED 5/15/2018 - 5/14/2019
4. TITLE AND SUBTITLE Phase 2 Study of AZD2014, a Dual mTORC1/mTORC1 Inhibitor, for NF2 Patients with Progressive or Symptomatic Meningiomas		5a. CONTRACT NUMBER W81XWH-16-1-0103
		5b. GRANT NUMBER
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S) Scott R. Plotkin, MD, PhD E-Mail: splotkin@partners.org		5d. PROJECT NUMBER
		5e. TASK NUMBER
		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Massachusetts General Hospital Boston, Massachusetts 02114-2554		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		
13. SUPPLEMENTARY NOTES		
14. ABSTRACT Meningiomas are common in neurofibromatosis 2 (NF2) patients with a cumulative incidence of 80% by 70 years of age. Meningiomas that progress despite surgery and radiation are an important unmet medical need for these patients. To date, no chemotherapy has demonstrated efficacy against NF2-related meningiomas. Our laboratory studies have shown that treatment of primary meningioma cells with AZD2014, a mTORC1/mTORC2 inhibitor, leads to decreased cell viability/proliferation. Thus, we hypothesize that AZD2014 will be effective in treating symptomatic or progressive meningiomas in NF2 patients. In this single arm, non-comparative, phase II trial, 18 patients will be treated with AZD2014 for recurrent or progressive intracranial meningioma. AZD2014 will be administered on a repeating basis at a dose of 125 mg twice daily for two consecutive days out of every seven days (1 cycle = 28 days). Treatment will continue until disease progression or intolerable side effects. An MRI of the brain, with and without contrast, will be obtained every 12 weeks to assess for disease response or stability using volumetric measurements. In year 2, 4 additional subjects were enrolled on the study and accrual was completed well in advance of the anticipated 30 months. In year 3, subject follow up was completed and analysis of blood samples was performed. Data analysis will continue in year 4 of the study.		

15. SUBJECT TERMS Meningioma; mTORC; vistusertib; neurofibromatosis 2					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified	Unclassified		19b. TELEPHONE NUMBER <i>(include area code)</i>

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

Table of Contents

	<u>Page</u>
1. Introduction.....	5
2. Keywords.....	5
3. Accomplishments.....	5
4. Impact.....	6
5. Changes/Problems.....	6
6. Products.....	6
7. Participants & Other Collaborating Organization.....	6
8. Special Reporting Requirements.....	7
9. Appendices.....	7

INTRODUCTION

Neurofibromatosis 2 (NF2) is a neurogenetic tumor suppressor syndrome with a birth prevalence of 1 in 25,000 to 1 in 33,000. Patients with NF2 are at increased risk for multiple tumor types, including schwannomas, meningiomas, and ependymomas. Meningiomas are common in NF2 patients with a cumulative incidence of 80% by 70 years of age without a clear gender bias. Meningiomas that progress despite surgery and radiation are an important unmet medical need for these patients. To date, no chemotherapy has demonstrated efficacy against NF2-related meningiomas, and therefore, effective salvage therapies are greatly needed. Our laboratory studies have shown that treatment of primary meningioma cells with AZD2014, a mTORC1/mTORC2 inhibitor, leads to decreased cell viability/proliferation. Thus, we hypothesize that AZD2014 will be effective in treating symptomatic or progressive meningiomas in NF2 patients. In this single arm, non-comparative, phase II trial, 18 patients will be treated with AZD2014 for recurrent or progressive intracranial meningioma. AZD2014 will be administered on a repeating basis at a dose of 125 mg twice daily for two consecutive days out of every seven days (1 cycle = 28 days). Treatment will continue until disease progression or intolerable side effects. An MRI of the brain, with and without contrast, will be obtained every 12 weeks to assess for disease response or stability using volumetric measurements.

KEYWORDS

Neurofibromatosis 2; meningioma; mTOR; TORC1; TORC2

ACCOMPLISHMENTS

This section describes the key research accomplishments associated with each task outlined in the approved Statement of Work during the grant.

Major Task 1. Obtain institutional approval for proposed clinical trial (months 1-6)

In year 1, we obtained IRB approval at MGH and USAMRMC Human Research Protection Office (HRPO) to enroll subjects in the clinical trial. The following subtasks were completed during the first 4 months of the study.

	Projected Timeline (month)	Actual Timeline (month)
Refine eligibility criteria, exclusion criteria, screening protocol	1	1
Finalize consent form & human subjects protocol	1	1
SRC** protocol submission	1-3	1
IRB** protocol submission	1-3	1
Submit Investigational New Drug (IND) application to the U.S. Food and Drug Administration	4	1
Submit for Military 2nd level IRB** review (ORP/HRPO)	5	3
Local SRC/IRB approval	5	4
HRPO approval	6	4

All stated goals for Major Task 1 are complete.

Major Task 2. Enroll subjects in clinical trial (month 7-36)

In year 1, we projected that 4/18 subjects would be enrolled on the clinical trial. As of 5/30/2017, a total of 14/18 subjects have been enrolled on the clinical trial. The last 4 subjects were enrolled by the end of quarter 1, year 2. Overall, the clinical trial enrollment was complete about 17 months ahead of schedule.

Major Task 3. Perform genetic and immunohistochemical analysis (months 7-36)

A second aim of the study is to perform molecular analyses of tumors and blood for correlation with response to AZD2014.

We have collected archival meningioma specimens in all 18 subjects enrolled on the study to date. In addition, blood samples from all 18 subjects are available. In year 3, we performed genetic analyses on 18 blood samples for patients enrolled in this study. A pathogenic variant in the *NF2* gene was identified in 10/18 subjects. In addition, we have performed immunohistochemical analyses of pS6 (as mTORC1 readout), pNDRG1, pAKT (as mTORC2 readout) on archival tumor specimens. This will enable analysis of drug response by a particular genetic mutation of *NF2*, mTORC1/mTORC2 activation status in meningiomas.

Major Task 4. Data analysis and presentation of results (months 12-48)

In year 3, we have begin data analysis with a goal of presenting results when appropriate. We anticipate presenting results at successful scientific conferences as the data matures. In year 4, we hope to understand the role of dual TORC1/2 inhibition by comparing these results to those from similar studies in NF2 patients using mTORC1 inhibitors (such as everolimus).

IMPACT

Nothing to report at this point in the study.

CHANGES/PROBLEMS

Nothing to report.

PRODUCTS

Nothing to report

PARTICIPANTS

Name	Scott Plotkin, MD, PhD
Project Role	Principal Investigator
Nearest person-month worked	2
Contribution to project	Dr. Plotkin serves a leadership role on this project and is coordinating the administrative and clinical aspects of the trial.
Funding support	N/A
Name	Vijaya Ramesh, PhD
Project Role	Co-Investigator
Nearest person-month worked	2
Contribution to project	Dr. Ramesh is the head of the research laboratory responsible for the correlative studies in this trial. She provides the laboratory infrastructure for genetic and immunohistochemical analysis of blood and tumor specimens.
Funding support	N/A
Name	Justin Jordan, MD, MPH
Project Role	Co-Investigator
Nearest person-month worked	1
Contribution to project	Dr. Jordan is a clinical specialist who has

	treated subjects on clinical trial, assisted with the administrative responsibilities of the study, and is helping to ensure that tissues are received in Dr. Ramesh's laboratory.
Funding support	N/A
Name	Alona Muzikansky, MA
Project Role	Statistician
Nearest person-month worked	1
Contribution to project	Ms. Muzikansky has provided statistical support for the clinical trial.
Funding support	N/A
Name	Nicola Gribbin, RN
Project Role	Research Nurse
Nearest person-month worked	1
Contribution to project	Ms. Gribbin has performed the duties of a research nurse in this study, helping with subject assessments, management of toxicity, and dispensing of AZD2014.
Funding support	N/A
Name	Annie Sposato
Project Role	Clinical research coordinator
Nearest person-month worked	1
Contribution to project	Ms. Sposato has coordinated the scheduling for subjects enrolled on the study.
Funding support	N/A

No other organizations were involved as partners.

SPECIAL REPORTING REQUIREMENTS

Not applicable

APPENDICES

None